Summary and analysis of clinical trials for the treatment of dry age-related macular degeneration
10.3980/j.issn.1672-5123.2024.8.11
- VernacularTitle:现阶段治疗干性年龄相关性黄斑变性临床试验的总结与分析
- Author:
Yunzhu KONG
1
;
Yi GONG
1
;
Yan SHAO
1
Author Information
1. Tianjin Medical University Eye Hospital;School of Optometry;Eye Institute;National Clinical Medical Research Center for Ocular Diseases, Tianjin Municipality Division;Tianjin Key Laboratory of Retinal Function and Diseases, Tianjin 300384, China
- Publication Type:Journal Article
- Keywords:
dry age-related macular degeneration;
treatment method;
clinical trial;
prevention;
treatment prospect
- From:
International Eye Science
2024;24(8):1240-1245
- CountryChina
- Language:Chinese
-
Abstract:
Age-related macular degeneration(ARMD)is one of the leading causes of irreversible blindness in the elderly. Anti-vascular endothelial growth factor(VEGF)drugs have become the first-line treatment for neovascular ARMD, which has greatly changed the prognosis. However, dry ARMD still lacks effective treatment means, focusing on prevention. At present, several clinical treatment methods are being explored, including antioxidant therapy, complement therapy, neuroprotective therapy, gene therapy, etc. This review mainly summarizes the existing clinical trials and their progress on the treatment of dry ARMD, in order to provide future prospects for the treatment of dry ARMD. A number of clinical trials have already produced promising results for the treatment of dry ARMD, and it is believed that more and more clinical trials will be successful in the near future to provide more effective treatments for patients with dry ARMD.
